EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

Integration of venetoclax into a fludarabine and melphalan conditioning regimen in patients aged 50 years and older with acute myeloid leukemia and myelodysplastic syndrome: Results from a phase 2 clinical trial

Xiaoyu Lai, Panpan Zhu, Luxin Yang, Lizhen Liu, Yibo Wu, Jimin Shi, Jian Yu, Yanmin Zhao, Guifang Ouyang, Yi Chen, Yishan Ye, Ping Zhang und 5 weitere

Cancer · 01.06.2026 · 132 (11)

DOI: 10.1002/cncr.70467 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer, online erschienen am 20.05.2026. Verfasst von Xiaoyu Lai und 16 weiteren Autor:innen. Beteiligte Einrichtung: Bone Marrow Transplantation Center of The First Affiliated Hospital and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejia…. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides. Die Arbeit nennt 38 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Zhejiang Provincial Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The optimal regimens for older adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) before allogeneic hematopoietic stem cell transplantation (allo‐HSCT) remain uncertain.

Methods

The authors conducted a multicenter phase 2 trial to evaluate the novel venetoclax, fludarabine, and melphalan (VFM) regimen in patients with AML or MDS aged 50 years and older. The VFM regimen consisted of venetoclax (400 mg daily on days −8 to −2), fludarabine (30 mg/m 2 daily on days −7 to − 3), and melphalan (120–140 mg/m 2 daily on day −2).

Results

Sixty patients (median age, 58 years; age range, 51–66 years) received the novel VFM conditioning regimen. The 2‐year disease‐free survival (DFS) rate was 75.0% (95% confidence interval [CI], 64.8%–86.8%), which was the primary end point. Two‐year rates of overall survival, graft‐versus‐host disease (GVHD)–free and recurrence‐free survival, nonrelapse mortality, and relapse were 78.3% (95% CI, 68.6%–89.5%), 61.6% (95% CI, 50.5%–75.3%), 13.3% (95% CI, 6.1%–23.3%), and 11.7% (95% CI, 5.1%–21.3%), respectively. Treatment‐related grade 2–3 nonhematologic adverse events occurred in 58% of patients, with no grade 4–5 nonhematologic toxicities. The cumulative incidence of grade 2–4 and grade 3–4 acute GVHD at day 100 was 5.0% (95% CI, 1.3%–12.7%) and 1.7% (95% CI, 0.1%–7.9%), respectively. The 2‐year cumulative incidence of moderate‐to‐severe chronic GVHD was 16.7% (95% CI, 8.5%–27.3%).

Conclusions

These findings support the feasibility of incorporating venetoclax into a fludarabine and melphalan conditioning regimen in older adults with AML/MDS. Notably, the low rates of GVHD and relapse associated with this venetoclax‐based conditioning regimen support further study of this platform [ClinicalTrials.gov Identifier: NCT05084027].

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelodysplastic SyndromesLeukemia, Myeloid, AcuteBridged Bicyclo Compounds, HeterocyclicSulfonamidesTransplantation ConditioningAntineoplastic Combined Chemotherapy ProtocolsHumansVidarabineAgedFemaleMiddle AgedMelphalanMaleHematopoietic Stem Cell TransplantationDisease-Free SurvivalGraft vs Host Disease

Stichwörter der Autor:innen

acute myeloid leukemiaconditioning regimenmyelodysplastic syndromeoldervenetoclax

Substanzen

venetoclaxBridged Bicyclo Compounds, HeterocyclicfludarabineVidarabineSulfonamidesMelphalan

Autor:innen und Institutionen

  • Bone Marrow Transplantation Center of The First Affiliated Hospital and Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
  • Institute of Hematology, Zhejiang University, Hangzhou, Zhejiang, China.
  • Zhejiang Province Engineering Research Center for Stem Cell and Immunity Therapy, Hangzhou, Zhejiang, China.
  • The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China.
  • The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.

ORCID-Profile: He Huang, Yi Luo

Förderung

  • National Natural Science Foundation of China
  • Zhejiang Provincial Natural Science Foundation of China

Zitieren

APA

Lai, X., Zhu, P., Yang, L., Liu, L., Wu, Y., Shi, J., Yu, J., Zhao, Y., Ouyang, G., Chen, Y., Ye, Y., Zhang, P., Sun, L., Zheng, W., Sun, J., Huang, H., & Luo, Y. (2026). Integration of venetoclax into a fludarabine and melphalan conditioning regimen in patients aged 50 years and older with acute myeloid leukemia and myelodysplastic syndrome: Results from a phase 2 clinical trial. Cancer, 132(11). https://doi.org/10.1002/cncr.70467

Vancouver

Lai X, Zhu P, Yang L, Liu L, Wu Y, Shi J, et al. Integration of venetoclax into a fludarabine and melphalan conditioning regimen in patients aged 50 years and older with acute myeloid leukemia and myelodysplastic syndrome: Results from a phase 2 clinical trial. Cancer. 2026;132(11). doi:10.1002/cncr.70467

BibTeX
@article{Lai2026,
  author = {Lai, Xiaoyu and Zhu, Panpan and Yang, Luxin and Liu, Lizhen and Wu, Yibo and Shi, Jimin and Yu, Jian and Zhao, Yanmin and Ouyang, Guifang and Chen, Yi and Ye, Yishan and Zhang, Ping and Sun, Lan and Zheng, Weiyan and Sun, Jie and Huang, He and Luo, Yi},
  title = {Integration of venetoclax into a fludarabine and melphalan conditioning regimen in patients aged 50 years and older with acute myeloid leukemia and myelodysplastic syndrome: Results from a phase 2 clinical trial},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {11},
  doi = {10.1002/cncr.70467}
}
Kostenlos starten →